Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | How the amyloidosis treatment landscape has transformed in recent years

Joan Bladé • 12 May 2022
COMy 2022
Amyloidosis Multiple Myeloma Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone Melphalan

Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, briefly discusses how the amyloidosis treatment landscape has transformed with the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone, and the exciting implications that this combination therapy has for the future of amyloidosis treatment. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Honoraria for lectures: Janssen, BMS, Amgen, Takeda, Oncopeptides

More from Joan Bladé

2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020
10:09
ISA 2020: continuing the amyloidosis conversation
Joan Bladé • 2 Sep 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals